Global Herpangina Treatment Market, By Virus (Coxsackie Virus A, Coxsackie Virus B, Enterovirus 71, Echovirus), Symptoms (High Fever, Sore Throat, Blisters Or Ulcers In The Throat And Mouth, Difficulty Swallowing, Loss Of Appetite, Headache, Neck Pain, Swollen Lymph Glands), Treatment (Topical Anesthetics, Ibuprofen or Acetaminophen, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Herpangina Treatment Market Analysis and Size
Herpangina mainly affects toddlers and children younger than 10 years old. Newborns, people with compromised immune systems and ones who are pregnant are at a higher risk of getting an infection that could be dangerous or life-threatening. The viruses that cause herpangina are very contagious and survive in environments outside the body for long periods. Herpangina generally clears up after a week to 10 days.
Data Bridge Market Research analyses a growth rate in the herpangina treatment market in the forecast period 2023-2030. The expected CAGR of the herpangina treatment market tend to be around 5.90% in the mentioned forecast period. The market was valued at USD 1.58 billion in 2022 and would grow to USD 2.5 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Herpangina Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Virus (Coxsackie Virus A, Coxsackie Virus B, Enterovirus 71, Echovirus), Symptoms (High Fever, Sore Throat, Blisters Or Ulcers In The Throat And Mouth , Difficulty Swallowing, Loss Of Appetite, Headache, Neck Pain, Swollen Lymph Glands), Treatment (Topical Anesthetics, Ibuprofen or Acetaminophen, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Hoffmann-La Roche Ltd. (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc (U.S.), AstraZeneca (U.K.), Abbvie, Inc. (U.S.), Bausch Health Companies Inc. (Canada), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Mylan N.V. (U.S.), Novartis AG (Switzerland), AstraZeneca (U.K.), Gilead Sciences, Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Merck & Co., Inc. (U.S.), AbbVie Inc. (U.S.), Vertex Pharmaceuticals Incorporated (U.S.), ViiV Healthcare group of companies (U.S.), Sanofi (France), Mitsubishi Chemical Group Corporation (Japan)
|
|
Market Opportunities
|
|
Market Definition
Herpangina is a type of infection that causes small blisters in mouth and throat, usually caused by a group of viruses known as enteroviruses. It is often misdiagnosed as another condition affecting children, called hand-foot-mouth disease (HFM). These both disorders cause oral blisters and ulcers but the location is slightly different. This infection is highly contagious and can easily spread person to person. This condition is not so common in adults as they have already built up the antibodies to fight the virus.
Herpangina Treatment Market Dynamics
Drivers
- Increase in the number of R&D activities
The market growth is boosted by an increase in the number of research activities. This will provide much beneficial opportunities for the market. The government is funding huge research and development (R&D) initiatives to encourage researchers and pharmaceutical companies to develop several novel medicines.
Opportunities
- The emergence of new varied treatments
The new evolving research organizations in the market are equipped with and utilize the knowledge of professionals in numerous clinical disciplines, leading to important advances in understanding HTLV-1 -related disorders and treatment. Treatment methods such as Acetaminophen or ibuprofen for fever, topical anesthetics for sores in the mouth and throat.
- Increasing Demand for Online Pharmacies
The rise in online access to medications and the rising culture of telemedicine and surge in the number of online pharmacies in developed countries create opportunities for market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily available.
Restraints/Challenges
- High Cost of Treatment Processes
The enormous expenditure required for the treatment processes impedes the market growth. Numerous market players make huge investments in developing new and advanced treatment procedures to faster the recovery process, and in return, the cost is increased.
This herpangina treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the herpangina treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Herpangina Treatment Market Scope
The herpangina treatment market is segmented on the basis of virus, symptoms, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Virus
- Coxsackie Virus A
- Coxsackie Virus B
- Enterovirus 71
- Echovirus
Symptoms
- High Fever
- Sore Throat
- Blisters Or Ulcers In The Throat And Mouth
- Difficulty Swallowing
- Loss Of Appetite
- Headache
- Neck Pain
- Swollen Lymph Glands
Treatment
- Topical Anesthetics
- Ibuprofen or Acetaminophen
- Others
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Herpangina Treatment Market Regional Analysis/Insights
The herpangina treatment market is analyzed and market size insights and trends are provided by virus, symptoms, treatment, distribution channel and end-user as referenced above.
The major countries covered in the herpangina treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market in the forecast period because of the rise in the prevalence of such disorders and favorable reimbursement scenario within the region.
Asia-Pacific is considered to grow over the coming years due to the rise in incidence of the disease and increase in expenditure on the prevention and diagnosis of infectious diseases in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Herpangina Treatment Market Share Analysis
The herpangina treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to herpangina treatment market
Key players operating in the herpangina treatment market include:
- Hoffmann-La Roche Ltd. (Switzerland)
- Takeda Pharmaceutical Company Limited (Japan)
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Abbvie, Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K).
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Gilead Sciences, Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Merck & Co., Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Vertex Pharmaceuticals Incorporated (U.S.)
- ViiV Healthcare group of companies (U.S.)
- Sanofi (France)
- Mitsubishi Chemical Group Corporation (Japan)
SKU-